文献速递临床试验与 GCP流行病学与生物统计

社区提供直接抗病毒药物治疗丙型肝炎:随机对照试验方案与挑战

Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
PubMed 文献 · Trials · 2018-07-16

该研究旨在评估在初级卫生保健服务中提供直接抗病毒药物(DAA)治疗丙型肝炎病毒(HCV)感染的有效性及其对HCV关怀级联的影响。研究在澳大利亚和新西兰的13个初级卫生保健服务中心招募HCV感染患者,随机分配至当地三级机构接受标准治疗或在初级卫生保健服务中心接受干预治疗,主要终点是开始DAA治疗并治愈的比例。研究同时反思了在HCV治疗变革时期开展该研究的挑战。

要点

  • 在初级卫生保健服务中提供DAA治疗可提高可及性和滞留护理。
  • 主要终点为开始DAA治疗并治愈的比例。
  • 研究在澳大利亚和新西兰的13个初级卫生保健服务中心开展。

核心结论

  • 本研究是首个真实世界随机对照模型研究,探索社区提供DAA治疗对HCV治疗 uptake 和治愈的影响。

研究设计与样本

  • 在澳大利亚和新西兰的13个初级卫生保健服务中心招募HCV感染患者,随机分配至当地三级机构治疗(标准治疗组)或初级卫生保健服务中心治疗(干预组)。

关键数值与推荐

  • 主要终点是开始DAA治疗并治愈的比例。

临床怎么用

  • 研究数据对制定消除HCV的卫生服务政策具有关键重要性。

局限性

  • 研究在HCV治疗和服务提供模式快速变革的时期进行,面临独特挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to treatment. Direct-acting antiviral (DAA) treatment can be provided in primary healthcare services (PHCS), improving accessibility, and, potentially, retention in care. Here, we describe our protocol for assessing the effectiveness of providing DAAs in PHCS, and the impact on the HCV care cascade. In addition, we reflect on the challenges of conducting a model of care study during a period of unprecedented change in HCV care and treatment. METHODS: Consenting patients with HCV infection attending 13 PHCS in Australia or New Zealand are randomized to receive DAA treatment at the local tertiary institution (standard care arm), or their PHCS (intervention arm). The primary endpoint is the proportion commenced on DAAs and cured. Treatment providers at the PHCS include: hepatology nurses, primary care practitioners, or, in two sites, a specialist physician. All PHCS offer opioid substitution therapy. DISCUSSION: The Prime Study is the first real-world, randomized, model of care study exploring the impact of community provision of DAA therapy on HCV-treatment uptake and cure. Although the study has faced challenges unique to this period of time characterized by changing treatment and service delivery, the data gained will be of critical importance in shaping health service policy that enables the elimination of HCV. TRIAL REGISTRATION: ClinicalTrials.gov , ID: NCT02555475 . Registered on 15 September 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wade AJ, Doyle JS, Gane E, et al. Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. Trials. 2018. PMID: 30012192. doi:10.1186/s13063-018-2768-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。